Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 6:29am EST - Canadian Markets open in 3 hours and 1 minute.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
GENENTECH INC (DNA)
On Nov 17:
80.43 USD
0.00 (0.00%)
MORE ON DNA
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
GENENTECH INC
(NYSE:DNA) Delayed quote data
Last Trade:
80.43 USD
Trade Time:
Nov 17
Change:
0.00 (0.00%)
Prev Close:
80.43
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
96.89
Day's Range:
N/A - N/A
52wk Range:
69.17 - 99.14
Volume:
0
Avg Vol
(3m)
:
0
Market Cap:
N/A
P/E
(ttm)
:
N/A
EPS
(ttm)
:
N/A
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Free Annual Reports
Add DNA to Portfolio
Download Data
HEADLINES
UPDATE - Sanofi says vaccines to help lift 2010 earnings
at Reuters
(Wed 3:00am)
Researchers find sex-specific lung cancer genes
at Reuters
(Tue 7:34pm)
Seattle Genetics 4Q loss narrows on higher revenue
AP
(Tue 6:18pm)
UPDATE - Biogen 4th-qtr profit up, outlook tops estimates
at Reuters
(Tue 11:32am)
UPDATE - Roche licenses new flu-fighting technology
at Reuters
(Mon, Feb 8)
Stocks for the Next Decade
at Motley Fool
(Thu, Feb 4)
UPDATE - Glaxo drops some drug research in efficiency drive
at Reuters
(Thu, Feb 4)
Drugmakers Pfizer, Roche disappoint with forecasts
at Reuters
(Wed, Feb 3)
Genentech share deal weighs on Roche
at FT.com
(Wed, Feb 3)
UPDATE - Roche profit misses forecast but confirms outlook
at Reuters
(Wed, Feb 3)
More Headlines for DNA...
ANALYST
EPS Est (next year)
(Dec-09)
:
N/A
EPS Est (in 2 years)
(Dec-10)
:
N/A
Avg Rec (current)*:
2.8
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
No business summary available for DNA.
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices